Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the safety of using the study drugs
bevacizumab and ipilimumab together, and the doses in combination which can be given to
people safely. This study also seeks to investigate whether using both study drugs lengthens
the amount of time before the participants melanoma worsens.